- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04984460
Morphological Detection of Liquid-based Thin-layer Film-making Fungi for Fungal Vaginitis in Multiple Hospitals
A Multicenter Clinical Study on Liquid-based Morphological Detection of Fungi
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230031
- The First Affiliated hospital of USTC
-
-
Guangdong
-
Zhongshan, Guangdong, China
- Zhongshan City People's Hospital
-
-
Jiangsu
-
Nantong, Jiangsu, China, 226001
- The Second Affiliated Hospital of Nantong University
-
Nantong, Jiangsu, China, 226006
- Affiliated Hospital of Nantong University
-
Nantong, Jiangsu, China
- Affiliated Nantong Hospital Of Shanghai University
-
Nantong, Jiangsu, China
- Nantong Maternal and Child Health Hospital
-
Qidong, Jiangsu, China
- Children's Hospital of Fudan University Qidong Branch
-
-
Jiangxi
-
Jiujiang, Jiangxi, China
- Jiujiang Maternal and Child Health Hospital
-
Nanchang, Jiangxi, China, 330006
- Jiangxi Maternal and Child Health Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200051
- Changning District Maternal and Child Health Care Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1. Samples from outpatient or inpatient clinics to be tested for fungal vaginitis.
- 2. A sample of one or more of the following characteristics. 2.1 Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.
2.2 Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.
- 3. The samples are vaginal secretions from the female body. Each sample should be the amount on one swab.
- 4. The sample is not in menstrual period.
- 5. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days.
Exclusion Criteria:
- 1. Cases with incomplete specimen collection;
- 2. Mixed vaginitis cases;
- 3. Abscission cases with incomplete follow-up.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
life-style counseling
A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased. Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd. |
Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased. Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd. Samples are human vaginal secretions. Each sample should be the amount on one swab. The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparing the positive detection rate of 3/4 different detection methods in the first phase.
Time Frame: From Aug. 1st to Dec. 31st, 2021
|
The positive coincidence rate (sensitivity), negative coincidence rate (specificity) and total coincidence rate (consistency) was compared, according to the P<0.05 was used to determine whether it was statistically significant.
|
From Aug. 1st to Dec. 31st, 2021
|
|
Calculating the proportion of the number of fungi in three different states in the map results of three/four detection methods.
Time Frame: From Aug. 1st, 2021 to Jan. 31st, 2022
|
Counting The number and proportion of mycelia, spores and blastospores, especially the percentage of cases of single spore (+) in all cases of fungus (+).
|
From Aug. 1st, 2021 to Jan. 31st, 2022
|
|
Counting the positive numbers of 4 or 6 liquid-based thin-layer fungal fluorescence morphological tests and fungal culture in the Stage 2_follow-up stage.
Time Frame: From Mar. 1, 2022 to Dec. 31st, 2022
|
the positive coincidence rate (sensitivity), negative coincidence rate (specificity) of 4 or 6 liquid-based thin-layer fungal fluorescence morphological tests
|
From Mar. 1, 2022 to Dec. 31st, 2022
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yuquan Zhang, Doctor, Affiliated Hospital of Nantong University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AHNantongU_YEZH_NTFS_V1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginitis
-
Amneal Pharmaceuticals, LLCCompletedAtrophic Vaginitis Due to MenopauseUnited States
-
Fayoum UniversityRecruitingAtrophic Vaginitis | Postmenopausal Atrophic VaginitisEgypt
-
Ain Shams UniversityNetherlands: Ministry of Health, Welfare and SportsUnknown
-
Tulane University Health Sciences CenterCompletedVaginitis Trichomonal or Due to TrichomonasUnited States
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Diseases | Atrophic VaginitisBrazil
-
Assiut UniversityUnknownTrichomonas Vaginalis Genotyping in Upper Egypt | Vaginitis Trichomonal
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyUnited States, Canada
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyGermany
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownAtrophic VaginitisChina